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Abstract
 
The promyelocytic leukemia protein (PML) gene of acute promyelocytic leukemia (APL) en-
codes a cell growth and tumor suppressor essential for multiple apoptotic signals. Daxx was
identified as a molecule important for the cytoplasmic transduction of the Fas proapoptotic
stimulus. Here, we show that upon mitogenic activation of mature splenic lymphocytes, Daxx
is dramatically upregulated and accumulates in the PML nuclear body (NB) where PML and
Daxx physically interact. In the absence of PML, Daxx acquires a dispersed nuclear pattern, and
activation-induced cell death of splenocytes is profoundly impaired. PML inactivation results in
the complete abrogation of the Daxx proapoptotic ability. In APL cells, Daxx is delocalized
from the NB. Upon retinoic acid treatment, which induces disease remission in APL, Daxx re-
localizes to the PML NBs. These results indicate that PML and Daxx cooperate in a novel NB-
dependent pathway for apoptosis and shed new light in the role of PML in tumor suppression.
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Introduction
 
The promyelocytic leukemia protein (PML)
 
1
 
 gene is in-
volved in reciprocal chromosomal translocations with the
retinoic acid receptor 
 
a
 
 (RAR
 
a
 
) locus that are specifically
found in almost 100% of cases of acute promyelocytic leu-
kemia (APL), a distinct subtype of myeloid leukemia (1–6).
This translocation leads to the production of a PML-
RAR
 
a
 
 chimeric oncoprotein, which is thought to inter-
fere with both PML and RAR/RA receptor X (RXR)
pathways (5, 6).
PML is a RING finger IFN-inducible protein typically
concentrated within discrete speckled nuclear structures
called PML nuclear bodies (NBs) (5–9). PML acts as a cell
growth and tumor suppressor, antagonizing initiation, pro-
motion, and progression of tumors of various histological
origins, and, particularly, of the lympho-hemopoietic com-
partment (10). PML is essential for the ability of Fas, TNF-
 
a
 
,
ceramide, and IFN to induce programmed cell death and is
required for DNA damage–induced apoptosis in mitogen-
activated splenic lymphocytes (11).
In APL cells, the presence of PML-RAR
 
a
 
 leads to the
delocalization of PML from the NBs and its accumulation
into aberrant nuclear microspeckled structures where PML,
RXR, and the PML-RAR
 
a
 
 oncoprotein colocalize. Upon
RA treatment, which induces the degradation of the onco-
protein, the terminal differentiation of the APL blasts and
the complete albeit transient remission of the disease, PML
and the other NB proteins reacquire their natural nuclear
localization (5, 9, 12–14). Thus, the deregulation of the
PML NB pathway by PML-RAR
 
a
 
 may play a crucial role
in tumorigenesis.
In agreement with the critical role of PML in apoptosis,
PML-RAR
 
a
 
 has a marked antiapoptotic function, and this
activity depends, at least in part, on its ability to deregulate
PML function (11, 15).
Daxx was originally identified as an adaptor molecule
that binds to the death domain of the Fas receptor (16).
Daxx has also been found to localize in the nucleus (17,
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Abbreviations used in this paper:
 
 APL, acute promyelocytic leukemia;
ASK1, apoptosis signal–regulating kinase 1; BFP, blue fluorescent protein;
DAPI, 4,6-diamino-2-phenylindole; FADD, Fas-associated death domain
protein; GFP, green fluorescent protein; Hsp90, heat shock protein 90;
JNK, c-Jun NH
 
2
 
-terminal kinase; NB, nuclear body; PML, promyelo-
cytic leukemia protein; RA, retinoic acid; RAR
 
a
 
 and RXR, RA recep-
tor 
 
a
 
 and RA receptor X, respectively; SD, synthetic dropout; TUNEL,
terminal deoxynucleotidyl–mediated dUTP nick end labeling.
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18). However, its nuclear function is unknown. Daxx acts
as a proapoptotic molecule that can enhance Fas-mediated
apoptosis, as well as the Fas-mediated activation of the
c-Jun NH
 
2
 
-terminal kinase (JNK) pathway through its inter-
action with the apoptosis signal–regulating kinase 1 (ASK1)
(19, 20). Targeted disruption of the Daxx gene in the
mouse results in early embryonic lethality, defining an im-
portant developmental role for this protein (18).
Here, we show that PML and Daxx participate in a
novel nuclear pathway for lymphocyte apoptosis. PML is
essential for both the proper localization of Daxx into the
NBs and its proapoptotic ability. The deregulation of this
pathway results in impaired lymphocyte activation–induced
cell death providing a further basis for the increased suscep-
tibility to lymphoma observed in PML
 
2
 
/
 
2
 
 mice. We also
find that in APL cells, Daxx is delocalized from the NB
along with PML, suggesting that the ability of PML-
RAR
 
a
 
 to interfere with this pathway might contribute to
the marked survival advantage that characterizes the malig-
nant promyelocyte.
 
Materials and Methods
 
Cell Culture and Transfection.
 
Cos-1 cells (American Type Cul-
ture Collection) were maintained in DMEM with high glucose
content and 10% FBS (Life Technologies). Mouse primary kera-
tinocytes and splenocytes were prepared as described previously
(11, 21). NB4 cells (American Type Culture Collection) were
grown in RPMI 1640 medium with 10% FBS. Passage 1 primary
keratinocytes and Cos-1 cells were transferred into 6-well dishes
or 100-mm plates 24 h before transfection. Transfections with
plasmid DNA were carried out using the SuperFect™ reagent
(Qiagen) following the manufacturer’s instructions.
 
Expression Vectors.
 
Full-length Daxx cDNA was obtained by
reverse transcription PCR from mouse testis total RNA, and
subcloned into pcDNA3.1 vector (Invitrogen). Murine Daxx and
human PML cDNAs were also subcloned in pEGFP (green fluo-
rescent protein [GFP]) and pEBFP (blue fluorescent protein
[BFP]) vectors (Clontech), respectively. Murine Daxx was also
subcloned in pcDNA3.1 together with a 6
 
3
 
His tag. His(6
 
3
 
)-
LacZ pcDNA3.1 was purchased from Invitrogen.
 
Indirect Immunofluorescence.
 
Primary mouse splenocytes and
keratinocytes were grown as above and then cytospun for 5 min
at 400 rpm directly onto glass slides. Cells were permeabilized by
incubation in methanol for 20 min at 
 
2
 
20
 
8
 
C. After washing
three times in PBS and blocking in PBS containing 10% heat-inac-
tivated goat serum (blocking buffer), the cells were incubated for
1 h at room temperature with the first antibody (a rabbit poly-
clonal anti-PML antibody, a gift from Dr. P.S. Freemont, Impe-
rial Cancer Research Fund, London, UK [11]; a mouse mono-
clonal (sc-8043), or a rabbit polyclonal (sc-7152) anti-Daxx
antibody, both from Santa Cruz Biotechnology). For detection,
fluorescein- or Texas red–conjugated horse anti–mouse IgG or
goat anti–rabbit IgG antibodies were diluted 1:200 in blocking
buffer. Cells were incubated with the appropriate secondary anti-
body in blocking buffer containing 1 ng/ml DAPI for 1 h at
room temperature, washed three times in PBS, and the slides
were mounted with a coverglass in Vectashield mounting me-
dium (Vector Laboratories). Slides were analyzed in the Sloan-
Kettering Institute Confocal Microscopy Core Facility.
 
Immunoprecipitation.
 
After transfection with plasmid DNA,
Cos-1 cells were washed in PBS, and cell lysates were prepared
by adding 1 ml of ice-cold E1A buffer (250 mM NaCl, 50 mM
Hepes, pH 7.0, 0.1% NP-40, 5 mM EDTA) supplemented with
a complete protease inhibitor cocktail (Boehringer Mannheim).
Either a mouse anti-PML mAb (1:50–1:100 dilution, sc-966;
Santa Cruz Biotechnology), a mouse anti-Daxx mAb (1:400 dilu-
tion, sc-8043; Santa Cruz Biotechnology), or a rabbit polyclonal
anti-Daxx antibody (1:400 dilution, sc-7152; Santa Cruz Bio-
technology) was added to 50 
 
m
 
l of lysate, and the solution was in-
cubated at 4
 
8
 
C overnight. For the endogenous coimmunoprecip-
itation, mouse primary splenocytes were Con A activated as
above for 3 d and washed in PBS. Cell lysates were prepared by
adding 1 ml of ice-cold E1A buffer. Either the rabbit polyclonal
anti-PML (1:500) or the mouse anti-Daxx mAb (1:400) was
added to the lysate, and the solution was incubated at 4
 
8
 
C over-
night. Protein A–agarose beads (Sigma Chemical Co.) were
added and incubated for 1 h with gentle rocking before pelleting
by centrifugation. The beads were washed three times in E1A
buffer and twice with PBS, and the immune complexes were re-
leased from the protein A–agarose beads by boiling in sample
buffer for 5 min. Cell lysates and immunoprecipitation products
were analyzed by Western blot.
 
Preparation of Subcellular Fractions.
 
Subcellular fractionation was
performed as described (22). In brief, cells were lysed in hypo-
tonic buffer (5 mM Tris, pH 7.4, 5 mM KCl, 1.5 mM MgCl
 
2
 
,
0.1 mM EGTA [pH 8.0], 1 mM dithiothreitol, 10 
 
m
 
g/ml aproti-
nin, 10 
 
m
 
g/ml leupeptin, 10 mM benzamidine, 1 mM PMSF, 0.2
mM Na
 
3
 
VO
 
4
 
) at 4
 
8
 
C for 30 min. After homogenization (20
strokes with a Dounce homogenizer B-pestle), samples were cen-
trifuged (2,000 
 
g
 
 for 5 min) to isolate the nuclei, which were lysed
in E1A buffer. Nuclear NP-40–insoluble fractions were lysed di-
rectly in SDS-sample buffer. The resulting supernatant was con-
sidered as cytosolic fraction.
 
Yeast Two-Hybrid Assay.
 
Yeast two-hybrid assays were per-
formed using MATCHMAKER Two-Hybrid System 2 (Clon-
tech). In brief, full-length Daxx and PML were subcloned into
pAS2-1 or pACT-2 vector. pAS2-1-Daxx and/or pACT-2-PML
were transformed into yeast strain Y187 containing a LacZ re-
porter under the control of a Gal4-responsive upstream activating
sequence (UAS), and colonies were grown on synthetic dropout
(SD)-Trp, SD-Leu, or SD-Trp/-Leu/-His plates. After 3 d, the
colonies were inspected for blue color development following
the manufacturer’s protocol. To quantitate the protein–protein
interactions, 
 
b
 
-galactosidase activity of yeast transformants (three
to four clones per transformation) grown in liquid culture was
determined using 
 
o
 
-nitrophenyl 
 
b
 
-
 
d
 
-galactopyranoside (ONPG)
as substrate, as per the manufacturer’s instructions (Hoffmann-La
Roche).
 
Purification of B Cells.
 
B and T splenic subpopulations were
stained with FITC-conjugated anti-B220 and anti-CD90 anti-
bodies (PharMingen) for 15 min and then washed and incubated
with magnetic beads conjugated with an anti-FITC antibody
(Miltenyi Biotec) for 5–10 min. After two washes, cells were sep-
arated on LS
 
1
 
 MACS separation columns (Miltenyi Biotec). The
purity of the various subpopulations was 
 
z
 
95% as assessed by
flow cytometric analysis of cells stained with an FITC-conjugated
anti-B220 and anti-CD90 antibodies (PharMingen).
 
Apoptosis Analysis.
 
Primary keratinocytes and splenocytes
were harvested and cytospun onto glass slides. Cells were fixed
with 4% paraformaldehyde in PBS for 30 min at room tempera-
ture and permeabilized in 0.1% Triton X-100, 0.1% sodium ci-
trate for 2 min at 4
 
8
 
C. After 1 h in blocking solution (PBS with
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10% goat serum) at room temperature, cells were incubated with
an anti-His mAb (Penta, 1:200; Qiagen). Cells were then stained
with a Texas red–conjugated anti–mouse antibody (1:200) di-
luted in the terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) reaction mixture (Roche) for
1 h at room temperature. Cells recognized by the anti-His anti-
body were scored for TUNEL positivity and nucleus condensa-
tion as apoptotic cells. In addition, apoptosis was scored by stain-
ing with propidium iodide and by evaluation of subdiploid DNA
content by FACS
 
®
 
 analysis.
 
Results
 
Daxx Localizes to Discrete Nuclear Regions upon Splenocyte
Activation.
 
We attempted to identify molecules that could
interact with PML in transducing the apoptotic stimulus in
mitogen-activated splenocytes. To this end, we searched
for proteins that colocalize with PML in the NBs of sple-
nocytes before and/or after Con A activation. Cytospins of
splenocytes obtained from PML
 
1
 
/
 
1
 
 mice were prepared ei-
ther immediately or after 3 d of culture in the presence of
Con A. Subsequently, the cells were subjected to coimmu-
nofluorescence with appropriate antibodies and an anti-
PML antibody that cross-reacted with the murine PML
(see Materials and Methods). Using an anti-Daxx mAb in
confocal microscopy, we observed that while at the steady-
state Daxx was localized in the cytosol, where it showed a
diffuse localization pattern, in Con A–activated splenocytes
Daxx was mainly localized in discrete speckled nuclear re-
gions (Fig. 1 A). The vast majority of the cells displayed a
speckled nuclear pattern with 
 
z
 
5.5 
 
6 
 
3.2 dots per cell
(Fig. 1 A). Similar results were obtained using a polyclonal
Daxx antibody (not shown).
We also observed that the immunofluorescence staining
of Daxx in splenocytes became much stronger after Con A
activation. To investigate whether this could be the result
of upregulated Daxx expression after Con A treatment, we
studied levels of Daxx expression in splenocytes before or
after Con A activation by Northern and Western blot anal-
yses (Fig. 1, B and C). After 72 h of Con A treatment, the
mRNA level of Daxx was markedly upregulated, suggest-
ing that Con A can induce Daxx expression at the tran-
scription level (Fig. 1, B and C). In addition, we analyzed
the protein levels of Daxx in the cytoplasmic and nuclear
soluble and insoluble fractions. We observed that before
Con A activation, Daxx is detected at very low levels and
exclusively in the cytoplasm (Fig. 1 C). Localization of
Daxx in the cytosol was also observed in Jurkat T lympho-
cytes and murine hepatocytes (our unpublished observa-
tions; and Weinberg, R.A., personal communication). By
contrast, upon Con A activation Daxx was strongly in-
duced and mainly found associated with both the nuclear
soluble and nuclear insoluble fractions (Fig. 1 C). Thus,
upon Con A treatment, Daxx is dramatically upregulated
and translocated from the cytosol to the nucleus.
Figure 1. Con A activation of
splenocytes induces Daxx ex-
pression. (A) Daxx localization
in NBs is induced upon Con A
activation. PML1/1 splenocytes,
before and after Con A activa-
tion, were immunostained with
anti-PML and anti-Daxx anti-
bodies. Both Daxx and PML dis-
play a strong staining upon Con
A activation. Single staining (a, b,
a9, and b9) and superimposed im-
ages (c and c9) are shown. The
nuclei were visualized by DAPI
staining (d and d9). Representa-
tive confocal pictures are shown.
Bar, 10 mM. (B) Upregulation of
Daxx mRNA expression upon
Con A treatment. Northern blot
analysis was performed on total
RNA from PML1/1 primary
splenocytes, before and after 72 h
of Con A activation using a
Daxx cDNA probe, which de-
tected a single 2.6-kb band. Nor-
malization with 28S RNA is also
shown. (C) Analysis of Daxx pro-
tein levels in cytosolic (C) and nu-
clear NP-40 (N)–soluble (SOL)
and insoluble fractions (INSOL).
Levels of heat shock protein 90
(Hsp90) were measured as a con-
trol of equal loading.
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Daxx Accumulates in the PML NBs.
 
We next investi-
gated whether the Daxx NBs would coincide with the
PML-NBs. To this end, we performed coimmunofluores-
cence analysis with the anti-Daxx mAb and polyclonal
anti-PML antibodies (see Materials and Methods). We de-
tected PML NBs in all cells before and after Con A activa-
tion (Fig. 1 A). However, although before Con A activa-
tion, the splenocytes displayed 4.5 
 
6 
 
1.5 NBs per cell, after
Con A the number of NBs increased up to twofold (9 
 
6 
 
4
per cell) and were much brighter (Fig. 1 A). Coimmuno-
fluorescence staining demonstrated a complete colocaliza-
tion of the Daxx dots with PML NBs, whereas not all PML
NBs contained Daxx (Fig. 1 A). Moreover, in our fraction-
ation experiments, a significant amount of Daxx was found
in the insoluble nuclear fraction (Fig. 1 C), in agreement
with the notion that the PML NBs are tightly associated
with the insoluble nuclear matrix (9). Thus, Daxx is local-
ized within the NBs upon splenocyte activation.
To further confirm that Daxx and PML colocalize in the
nucleus, we transiently transfected Cos-1 cells with vectors
expressing Daxx-GFP and PML-BFP. We analyzed Daxx
and PML localization in formaldehyde-fixed cells by con-
focal microscopy. Daxx was found only associated with dis-
crete NBs that coincided with the PML-specific NBs. In
the same field, we could also detect the presence of cells
transfected with either PML or Daxx alone. Interestingly,
in cells expressing only Daxx, its localization was both nu-
clear speckled and nuclear diffuse. This indeed suggested
that in the presence of the overexpressed PML, the diffuse
Daxx protein was recruited to the NBs (Fig. 2 A). Daxx
Figure 2. Daxx and PML
colocalize in NBs and physically
interact. (A) Colocalization of
transfected Daxx and PML. Cos-1
cells cotransfected with GFP-
Daxx and BFP-PML were ana-
lyzed by confocal microscopy.
Green dots (GFP) are Daxx spe-
cific, blue dots (BFP) are PML
specific, and turquoise dots (GFP
plus BFP) represent colocalizing
proteins. Orange and white ar-
rows indicate cells transfected
with Daxx only and with PML
only, respectively. Representa-
tive pictures are shown. Bar, 10
mM. (B) Coimmunoprecipita-
tion of transfected Daxx and
PML in Cos-1 cells. The left
panel shows that PML is specifi-
cally detected in the Daxx im-
munoprecipitant, and the right
panel shows that Daxx is co-
immunoprecipitated with PML.
The whole cell lysates (inputs)
used for the immunoprecipitation
are also included to display the
migration of specific immunore-
active species. The anti–human
PML antibody used for the
coimmunoprecipitation analysis
does not cross-react with the en-
dogenous monkey PML. How-
ever, Cos-1 cells do express
PML as revealed by Northern
blot analysis. (C) Coimmuno-
precipitation of endogenous
Daxx and PML in Con A–acti-
vated PML1/1 and PML2/2
splenocytes. The left panel shows
that Daxx is specifically detected
in the PML immunoprecipitant,
and the right panel shows that
PML is coimmunoprecipitated
with Daxx. The migration of
specific immunoreactive species
detected in the whole cell lysates is also shown. As expected, the endogenous Daxx was coimmunoprecipitated along with PML in PML1/1 but not in
PML2/2 cells. (D) Yeast two-hybrid assay between the full-length Daxx and PML. Yeast strain Y187 was transformed with pAS2-1-Daxx and/or
pACT-2-PML. Three to four colonies per transformation were grown in liquid culture, and the b-galactosidase expression (b-Gal) was determined using
ONPG as substrate. The expression level of b-galactosidase measured by quantitative liquid assays in the cotransformed colonies was z50-fold higher
than that in the single-transformed colonies.
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and PML colocalization in nuclear speckles was also ob-
served in living cells by a phase–contrast fluorescent mi-
croscope as well as in Cos cells transiently transfected with
untagged PML and Daxx, where immunofluorescence
analysis using anti-PML and anti-Daxx antibodies was car-
ried out along with 4,6-diamino-2-phenylindole (DAPI)
staining (not shown).
 
PML and Daxx Physically Interact.
 
To test whether
Daxx and PML could physically interact, we cotransfected
Cos-1 cells with untagged PML and Daxx expression vec-
tors (pSG5-PML and pcDNA3.1-Daxx) and performed
coimmunoprecipitation experiments (see Materials and
Methods). Coprecipitated PML or Daxx was detected by
Western blot with anti-Daxx or anti-PML antibodies, re-
spectively (Fig. 2 B), thus indicating that PML and Daxx
interact in vivo. The anti–human PML antibody we have
used does not cross-react with the endogenous monkey
PML. However, Cos-1 cells do express PML as revealed by
Northern blot analysis (not shown).
We next investigated whether endogenous PML and
Daxx would physically interact in Con A–stimulated pri-
mary splenocytes. Indeed, endogenous PML and Daxx
proteins could be reciprocally coimmunoprecipitated in
these cells (Fig. 2 C).
To further prove physical interaction between Daxx and
PML, we used a yeast two-hybrid system. Full-length
Daxx was linked to the Gal4 DNA binding domain in a
pAS2-1 vector, and full-length PML was linked to the
Gal4 activation domain in a pACT-2 vector (see Materials
and Methods). In these assays, PML and Daxx were also
Figure 3. PML is required for
the NB localization of Daxx. (A)
Immunofluorescence analysis of
Daxx in PML2/2 splenocytes.
Splenocytes, before and after
Con A activation, were immu-
nostained with anti-PML and
anti-Daxx antibodies. Single
staining (a, b, a9, and b9) and su-
perimposed images (c and c9) are
shown. The nuclei were visual-
ized by DAPI staining (d and d9).
Representative confocal pictures
are shown. Bar, 10 mM. (B)
Western blot analysis of nuclear
extract from PML1/1 and
PML2/2 splenocytes, before and
after Con A activation. Hsp90
protein levels are shown as a
control of equal loading.
Figure 4. Daxx is selectively induced in B lymphocytes. PML1/1 and
PML2/2 splenocytes were treated with Con A and at 72 h B and T sub-
populations were obtained (Materials and Methods). Daxx expression lev-
els at 0 and 72 h were measured in B and T cells by Western blot with the
polyclonal anti-Daxx antibody. The differential expression of Daxx is also
visible in extracts from untreated B and T cells upon longer exposure (not
shown). Hsp90 was used as a normalization marker for protein input.
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found to interact (Fig. 2 D). All together, these data dem-
onstrate that Daxx can physically interact with PML in
vivo, under physiological conditions.
 
PML Is Required for the Localization of Daxx in the NBs.
 
To test whether PML would be required for NB localiza-
tion of Daxx, we performed immunofluorescence analysis
of Daxx localization in PML
 
2
 
/
 
2
 
 and PML
 
1
 
/
 
1
 
 splenocytes
before and/or after Con A activation (Fig. 3 A). Before
Con A activation, the cytoplasmic localization of Daxx was
indistinguishable between PML
 
2
 
/
 
2
 
 and PML
 
1
 
/
 
1
 
 spleno-
cytes. However, in activated PML
 
2
 
/
 
2
 
 splenocytes, Daxx
failed to localize in the NBs, and acquired a diffused,
patchy, nuclear localization pattern (Fig. 3 A). Neverthe-
less, the induction of Daxx was unaffected by the absence
of PML, as Daxx expression in PML
 
2
 
/
 
2
 
 and PML
 
1
 
/1 nu-
clear samples was virtually indistinguishable by Western
blot analysis (Fig. 3 B).
Daxx Is Differentially Upregulated in B Lymphocytes.
Upon mitogenic activation of splenocytes, we noticed the
presence of two distinct lymphocyte populations: cells that
expressed Daxx at very high levels (Daxxh) and cells ex-
pressing low levels of Daxx (Daxxl) (not shown). There-
fore, we tested whether this would be due to a differential
regulation of Daxx expression in the two main splenic pop-
ulations, B and T cells. B and T splenocytes were isolated
after Con A stimulation by magnetic positive selection with
an anti-B220 antibody and an anti-CD90 antibody, respec-
tively (see Materials and Methods). We analyzed Daxx ex-
pression levels by Western blot in these two subpopula-
tions. We observed that Daxx was induced in both B and T
cells. However, much higher levels were detected in B cells
(up to 10-fold; Fig. 4). These results were confirmed by
immunofluorescence analysis (not shown).
Activation-induced Cell Death Is Profoundly Impaired in
PML2/2 B Lymphocytes. During Con A activation, a large
number of B lymphocytes underwent programmed cell
death, and after 96 h the remaining cell population was al-
most entirely composed by T lymphocytes (not shown).
The induction of cell death coincided with the induction
of Daxx and its redistribution to the NBs. Since in PML2/2
splenocytes, Daxx was induced but did not localize to the
NBs, we tested whether upon Con A stimulation the delo-
calization of Daxx would affect the induction of apoptotic
Figure 5. Daxx induction correlates with B
cell apoptosis. PML1/1 and PML2/2 spleno-
cytes were treated with Con A. At 0, 24, 48,
and 72 h after stimulation, B lymphocytes were
isolated (see Materials and Methods) and scored
for apoptosis by in situ TUNEL assay (A) or
by cytometric analysis of subdiploid DNA con-
tent (B).
Figure 6. PML is required for the ability of Daxx to induce apoptosis.
(A) Time course of apoptosis in PML1/1 and PML2/2 keratinocytes
transfected with His(63)-Daxx or, as control, His(63)-LacZ. Apoptotic
cells were scored by TUNEL as described in B. The values are expressed
as mean percentage of apoptosis 6 SD (n 5 3). (B) TUNEL staining of
PML1/1 (top) and PML2/2 (bottom) keratinocytes 24 h after transfec-
tion. Transfected cells were recognized by immunofluorescence staining
with an anti-His mAb. His(63)-positive, red; TUNEL-positive, green;
DAPI, blue. White arrows point to His(63)-positive nonapoptotic
(TUNEL-negative) cells; red arrowheads point to His(63)-positive apop-
totic cells (yellow). The pictures were taken with an Olympus fluores-
cence microscope.
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cell death. Indeed, in a time course after Con A stimulation
the percentage of apoptotic cells was much lower in
PML2/2 than in PML1/1 splenic B lymphocytes (Fig. 5, A
and B).
The Proapoptotic Ability of Daxx Is Abrogated in PML2/2
Cells. We next investigated whether Daxx upregulation
would induce apoptosis in cells that express PML, and
whether its proapoptotic ability would be affected in the
absence of PML. To this end, we used PML2/2 and
PML1/1 primary keratinocytes. These cells express PML
and can be easily transfected (21, 23). Furthermore, as in
splenocytes, in primary keratinocytes PML and Daxx colo-
calize in the NBs, whereas Daxx is delocalized from the
NB in PML2/2 keratinocytes (not shown). We transfected
PML1/1 and PML2/2 keratinocytes with a His(63)-tagged
Daxx expression vector or, as control, a His(63)-tagged
LacZ vector. After transfection, cells were harvested at 24
and 48 h and scored for apoptosis by in situ TUNEL analy-
sis (see Materials and Methods; Fig. 6 A). Overexpression
of Daxx resulted in induction of apoptosis in PML1/1 pri-
mary keratinocytes, whereas this activity was completely
abrogated in the absence of PML (Fig. 6, A and B). Analy-
sis of nuclear condensation upon DAPI staining gave com-
parable results (not shown). Thus, the inactivation of PML
selectively impairs Daxx-induced apoptosis.
Daxx is Delocalized from the NBs in APL Cells. We next
studied the localization of Daxx in APL cells by immu-
nofluorescence analysis. As discussed previously, PML is
delocalized from the NB in APL cells that contain the
PML-RARa fusion protein due to t(15,17) translocation
(5). This fusion protein is present in the APL cell line NB4
(5). Staining of NB4 cells with anti-PML antibody revealed
the PML protein predominantly in nuclear microspeckles
(Fig. 7). Daxx also displayed an aberrant localization pattern
accumulating in microspeckles (Fig. 7), the majority of
which did not appear to colocalize with the PML mi-
crospeckles (Fig. 7). Treatment of NB4 cells with RA
causes relocalization of PML to the NBs (5). In RA-treated
NB4 cells, Daxx was relocalized to the NB, along with
PML (Fig. 7). These observations further demonstrate that
the normal localization pattern of Daxx requires PML and
intact NBs as has been shown for other NB proteins such as
Sp100 (9, 12–14).
Discussion
This study leads to the definition of a PML/NB-depen-
dent function of Daxx that is indispensable for its proapop-
totic function. Mitogenic stimuli such as Con A or LPS
plus IL-4 (not shown) induce the upregulation and/or re-
localization of Daxx into the PML NBs. Inactivation of
PML results in the deregulation of this process and im-
paired apoptosis of mature splenic B lymphocytes upon mi-
togenic stimuli.
The impaired ability of PML2/2 B lymphocytes to die
provides a further rationale for the increased susceptibility
of PML2/2 mice to lymphomas (10). Furthermore, the
identification of a critical role for PML in the induction of
apoptosis by Daxx and the aberrant localization pattern of
Daxx observed in APL cells provide a further basis for the
resistance of the APL leukemic blasts to multiple apoptotic
stimuli (11, 15). Although RA by itself induces differentia-
tion and not apoptosis in APL cell lines such as NB4 (24;
and our unpublished observations), the relocalization of
Daxx to the NBs upon RA treatment could render the
APL cells sensitive to proapoptotic stimuli.
It has been shown that Daxx may serve as an adaptor of
Fas (16), and an activator of ASK1 upon a Fas apoptotic
stimulus (19). The activation of ASK1 results in the phos-
phorylation and activation of JNK (19). JNK activation
leads to phosphorylation of c-Jun, which in turn may regu-
late transcription of genes relevant for apoptosis, possibly
inducing the activation of caspases. This pathway can oper-
ate in parallel to the Fas–Fas-associated death domain
(FADD) association, which couples Fas to procaspase 8
within the death-inducing signaling complex (DISC), lead-
ing to the cascade of caspase proteolytic activation. How-
ever, the Fas-dependent activation of JNK through Daxx
does not seem to be sufficient for proper transduction of
the Fas apoptotic stimulus since a Fas mutant that selec-
Figure 7. Daxx is delocalized
in the NB4 cells and relocalized
to the NB upon RA treatment.
NB4 cells were grown with or
without 1 mM RA for 24 h be-
fore harvest. Cells were immu-
nostained with a polyclonal anti-
Daxx antibody and an anti-PML
mAb. Single staining (a, b, a9,
and b9), superimposed images (c
and c9), and DAPI staining (d and
d9) are shown. Representative
confocal pictures are shown. Bar,
10 mM.
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tively binds Daxx but not FADD is profoundly impaired in
cell death induction (20). The transduction of the Fas signal
to Jun does not seem to be affected in the absence of PML
since Jun phosphorylation upon Fas stimulation is not im-
paired in PML2/2 activated splenocytes (not shown). Thus,
the Daxx-PML NB pathway for apoptosis may act inde-
pendently of the Fas-Daxx-JNK-Jun signal transduction
pathway. However, this does not exclude the possibility
that Fas could act through the Daxx-PML-NB pathway,
supported by the fact that the ability of Daxx to potentiate
Fas-induced apoptosis is completely abrogated in PML2/2
cells (not shown). It is therefore tempting to speculate that
Daxx could potentiate Fas-induced apoptosis through a
JNK-independent PML NB–dependent mechanism, in
agreement with the marked impairment in Fas-induced ap-
optosis observed in PML2/2 cells and mice (11).
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